Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
A prospective one-arm study of pegylated liposomal doxorubicin combined with anlotinib for
neoadjuvant treatment of locally advanced soft tissue sarcoma.